Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV - PubMed (original) (raw)
Comparative Study
Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV
I Ourmanov et al. J Virol. 2000 Mar.
Abstract
Prior studies demonstrated that immunization of macaques with simian immunodeficiency virus (SIV) Gag-Pol and Env recombinants of the attenuated poxvirus modified vaccinia virus Ankara (MVA) provided protection from high levels of viremia and AIDS following challenge with a pathogenic strain of SIV (V. M. Hirsch et al., J. Virol. 70:3741-3752, 1996). This MVA-SIV recombinant expressed relatively low levels of the Gag-Pol portion of the vaccine. To optimize protection, second-generation recombinant MVAs that expressed high levels of either Gag-Pol (MVA-gag-pol) or Env (MVA-env), alone or in combination (MVA-gag-pol-env), were generated. A cohort of 24 macaques was immunized with recombinant or nonrecombinant MVA (four groups of six animals) and was challenged with 50 times the dose at which 50% of macaques are infected with uncloned pathogenic SIVsmE660. Although all animals became infected postchallenge, plasma viremia was significantly reduced in animals that received the MVA-SIV recombinant vaccines as compared with animals that received nonrecombinant MVA (P = 0.0011 by repeated-measures analysis of variance). The differences in the degree of virus suppression achieved by the three MVA-SIV vaccines were not significant. Most importantly, the reduction in levels of viremia resulted in a significant increase in median (P < 0.05 by Student's t test) and cumulative (P = 0.010 by log rank test) survival. These results suggest that recombinant MVA has considerable potential as a vaccine vector for human AIDS.
Figures
FIG. 1
Representation of recombinant MVA virus genomes. Insertion of the expression cassette consisting of the sequences coding the SIVsmH-4 env precursor regulated by the synthetic early-late promoter (S.E/L) and the β-gal gene regulated by the vaccinia virus early-late P7.5 promoter is indicated by dashed lines to the site of deletion II within the MVA genome. Insertion of a cassette containing the sequences coding the SIVsmH-4 gag-pol precursor regulated by the S.E/L promoter and the GUS gene regulated by the P7.5 promoter is indicated by dashed lines to the site of deletion III. The directions of promoters and open reading frames are indicated.
FIG. 2
Expression of SIV proteins in monkey cell line BS-C-1 infected with recombinant MVA viruses. Radioimmunoprecipitation of viral proteins from culture supernatants (panels A and B) and cell extracts (panel C) of BS-C-1 monkey cells infected with different MVA-SIV recombinant viruses. Extracts shown in panel A were immunoprecipitated with plasma from an SIV-infected macaque, and extracts shown in panels B and C were immunoprecipitated with a macaque SIVsm-gp120-specific monoclonal antibody, IgG-201 (23). Lanes 1, immunoprecipitation from mock-infected cells; lanes 2, cells infected with nonrecombinant MVA; lanes 3, recombinant MVA-env; lanes 4, original MVA-SIV recombinant virus; lanes 5, MVA-gag-pol-env; lanes 6, MVA-gag-pol. Molecular mass markers are listed at the right in kilodaltons.
FIG. 3
Production of SIV-like particles from BSC-1 cells 24 h after infection with the MVA-gag-pol-env recombinant virus. Electron micrograph of infected cells with immature and mature SIV-like particles (panel A; magnification, ×54,000) and detailed pictures of mature VLPs (panel B; magnification, ×85,000) and stages of VLPs budding from the cell surface and maturing (panel C; magnification, ×68,000).
FIG. 4
Anti-SIVsmH-4 gp130 ELISA antibody titers in sera of immunized and control macaques. Six macaques per group were inoculated four times (open diamonds) with recombinant or nonrecombinant MVA and challenged 4 weeks later with SIVsmE660 (filled diamonds). Serial dilutions of plasma were incubated with recombinant SIVsmH-4 gp130 bound to microtiter plates treated by lectin from G. nivalis. End-point titers were defined as the reciprocal of the highest sera dilution that gave an optical absorbance at least two standard deviations greater in value than average values obtained with negative control sera.
FIG. 5
Plasma viral load in immunized and control macaques after challenge with uncloned SIVsmE660. Sequential levels of plasma viral RNA over the first 45 weeks after SIV challenge are shown for animals immunized prior to challenge with MVA-gag-pol, MVA-env, MVA-gag-pol-env, or MVA. Plasma viral load was determined by real-time RT-PCR as described in Materials and Methods. Results are expressed as number of copies of SIV genomic RNA equivalent per milliliter of plasma. Plasma samples having values under assay threshold sensitivity were given a value of 800 copy eq/ml. Animals sacrificed because of clinical manifestations of AIDS (ἀ) and the animal that died of causes unrelated to AIDS (✞) are labeled.
FIG. 6
Geometric means of plasma viral load values for groups of immunized and control macaques after challenge with uncloned SIVsmE660. Significant reductions in geometric mean plasma viral load were observed in macaques immunized prior to SIV challenge with recombinant MVA expressing SIVsmH-4 proteins Gag-Pol, Env, or Gag-Pol-Env as compared to those immunized with nonrecombinant MVA (repeated measures ANOVA, P = 0.0011). The error bars represent the standard errors of the means of duplicated measurements for six macaques in each group.
FIG. 7
Peripheral blood CD4+ T-lymphocyte levels in immunized and control macaques infected with uncloned SIVsmE660. Sequential levels of peripheral CD4+ T cells over the first 45 weeks after SIV challenge are shown for animals immunized prior to challenge with MVA-gag-pol, MVA-env, MVA-gag-pol-env, or MVA. Animals sacrificed because of clinical manifestations of AIDS (ἀ) and the animal that died of causes unrelated to AIDS (✞) are labeled. CD4+ T-lymphocyte levels were evaluated by fluorescence-activated cell sorting on whole heparinized blood samples using methods previously described (33).
FIG. 8
Survival rates for immunized and control macaques. Kaplan-Meier plot of cumulative survival rates in the first 590 days after challenge indicates significant differences between MVA-immunized- and MVA-SIV-immunized macaques.
Similar articles
- Immunization with a modified vaccinia virus expressing simian immunodeficiency virus (SIV) Gag-Pol primes for an anamnestic Gag-specific cytotoxic T-lymphocyte response and is associated with reduction of viremia after SIV challenge.
Seth A, Ourmanov I, Schmitz JE, Kuroda MJ, Lifton MA, Nickerson CE, Wyatt L, Carroll M, Moss B, Venzon D, Letvin NL, Hirsch VM. Seth A, et al. J Virol. 2000 Mar;74(6):2502-9. doi: 10.1128/jvi.74.6.2502-2509.2000. J Virol. 2000. PMID: 10684264 Free PMC article. - Therapeutic immunization with Modified Vaccinia Virus Ankara (MVA) vaccines in SIV-infected rhesus monkeys undergoing antiretroviral therapy.
Uberla K, Rosenwirth B, Ten Haaft P, Heeney J, Sutter G, Erfle V. Uberla K, et al. J Med Primatol. 2007 Feb;36(1):2-9. doi: 10.1111/j.1600-0684.2006.00190.x. J Med Primatol. 2007. PMID: 17359459 - Containment of simian immunodeficiency virus infection in vaccinated macaques: correlation with the magnitude of virus-specific pre- and postchallenge CD4+ and CD8+ T cell responses.
Hel Z, Nacsa J, Tryniszewska E, Tsai WP, Parks RW, Montefiori DC, Felber BK, Tartaglia J, Pavlakis GN, Franchini G. Hel Z, et al. J Immunol. 2002 Nov 1;169(9):4778-87. doi: 10.4049/jimmunol.169.9.4778. J Immunol. 2002. PMID: 12391187
Cited by
- Exploring HIV Vaccine Progress in the Pre-Clinical and Clinical Setting: From History to Future Prospects.
Kaur A, Vaccari M. Kaur A, et al. Viruses. 2024 Feb 27;16(3):368. doi: 10.3390/v16030368. Viruses. 2024. PMID: 38543734 Free PMC article. Review. - Therapeutic vaccination of SIV-infected, ART-treated infant rhesus macaques using Ad48/MVA in combination with TLR-7 stimulation.
Bricker KM, Obregon-Perko V, Uddin F, Williams B, Uffman EA, Garrido C, Fouda GG, Geleziunas R, Robb M, Michael N, Barouch DH, Chahroudi A. Bricker KM, et al. PLoS Pathog. 2020 Oct 26;16(10):e1008954. doi: 10.1371/journal.ppat.1008954. eCollection 2020 Oct. PLoS Pathog. 2020. PMID: 33104758 Free PMC article. - A recombinant herpesviral vector containing a near-full-length SIVmac239 genome produces SIV particles and elicits immune responses to all nine SIV gene products.
Shin YC, Bischof GF, Lauer WA, Gonzalez-Nieto L, Rakasz EG, Hendricks GM, Watkins DI, Martins MA, Desrosiers RC. Shin YC, et al. PLoS Pathog. 2018 Jun 18;14(6):e1007143. doi: 10.1371/journal.ppat.1007143. eCollection 2018 Jun. PLoS Pathog. 2018. PMID: 29912986 Free PMC article. - Generation of Recombinant Vaccinia Viruses.
Wyatt LS, Earl PL, Moss B. Wyatt LS, et al. Curr Protoc Protein Sci. 2017 Aug 1;89:5.13.1-5.13.18. doi: 10.1002/cpps.33. Curr Protoc Protein Sci. 2017. PMID: 28762491 Free PMC article. - A Simple Mouse Model for the Study of Human Immunodeficiency Virus.
Kim KC, Choi BS, Kim KC, Park KH, Lee HJ, Cho YK, Kim SI, Kim SS, Oh YK, Kim YB. Kim KC, et al. AIDS Res Hum Retroviruses. 2016 Feb;32(2):194-202. doi: 10.1089/AID.2015.0211. Epub 2015 Dec 17. AIDS Res Hum Retroviruses. 2016. PMID: 26564392 Free PMC article.
References
- Abimuki A G, Robert-Guroff M, Benson J, Tartaglia J, Paoletti E, Gallo R C, Markham P D, Franchini G. Long-term survival of SIVmac251-infected macaques previously immunized with NYVAC-SIV vaccines. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;15:S78–S85.
- Almond N, Kent K, Cranage M, Rud E, Clarke B, Stott E J. Protection by attenuated simian immunodeficiency virus in macaques against challenge with virus-infected cells. Lancet. 1995;345:1342–1344. - PubMed
- Almond N M, Heeney J L. AIDS vaccine development in primate models. AIDS. 1998;12(Suppl. A):S133–S140. - PubMed
- Altenburger W, Suter C P, Altenburger J. Partial deletion of the human host range gene in attenuated vaccinia virus MVA. Arch Virol. 1989;105:15–27. - PubMed
- Andersson S, Makitalo B, Thorstensson R, Franchini G, Tartaglia J, Limbach K, Paoletti E, Putkonen P, Biberfeld G. Immunogenicity and protective efficacy of a human immunodeficiency virus type 2 recombinant canarypox (ALVAC) vaccine candidate in cynomolgus monkeys. J Infect Dis. 1996;174:977–985. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials